MNG1129
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.502
- SPERMATOGENESIS+0.355
- COAGULATION+0.337
- PEROXISOME+0.285
- APICAL_SURFACE+0.252
- KRAS_SIGNALING_DN+0.216
- MYC_TARGETS_V1+0.188
- ESTROGEN_RESPONSE_LATE+0.183
- HEDGEHOG_SIGNALING+0.138
- FATTY_ACID_METABOLISM+0.137
Top 10 suppressed
- TGF_BETA_SIGNALING-0.443
- TNFA_SIGNALING_VIA_NFKB-0.406
- IL6_JAK_STAT3_SIGNALING-0.357
- P53_PATHWAY-0.348
- WNT_BETA_CATENIN_SIGNALING-0.326
- PI3K_AKT_MTOR_SIGNALING-0.300
- MYC_TARGETS_V2-0.298
- MITOTIC_SPINDLE-0.297
- UV_RESPONSE_DN-0.257
- UNFOLDED_PROTEIN_RESPONSE-0.237
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1144 | — | — | 0.781 |
| 2 | SRR1433750 | GTEX | — | 0.751 |
| 3 | SRR8943039 | — | — | 0.748 |
| 4 | MNG543 | — | — | 0.726 |
| 5 | SRR5088822 | — | — | 0.718 |
| 6 | MNG854 | — | — | 0.717 |
| 7 | MNG1052 | — | — | 0.716 |
| 8 | MNG250 | — | — | 0.714 |
| 9 | SRR1316963 | GTEX | — | 0.708 |
| 10 | 66326_S124 | — | cohortA1 | 0.706 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.502 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.355 | Inavolisib | — uncovered |
| COAGULATION | 0.337 | Binimetinib | — uncovered |
| PEROXISOME | 0.285 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.252 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.216 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.188 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.183 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.138 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.137 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.093 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.084 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.075 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.068 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.067 | Inavolisib | — uncovered |
| MYOGENESIS | 0.048 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.041 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.039 | Inavolisib | — uncovered |
| COMPLEMENT | 0.030 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.003 | Inavolisib | — uncovered |